Piper Sandler Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,013.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective cut by Piper Sandler from $1,195.00 to $1,013.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Sanford C. Bernstein cut their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Bank of America reissued an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,004.57.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $687.27 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The business’s 50 day moving average price is $724.48 and its 200 day moving average price is $930.31. The company has a market cap of $75.52 billion, a price-to-earnings ratio of 17.01, a PEG ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals has a one year low of $666.25 and a one year high of $1,211.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Creative Planning increased its holdings in Regeneron Pharmaceuticals by 11.5% in the second quarter. Creative Planning now owns 9,615 shares of the biopharmaceutical company’s stock valued at $10,106,000 after buying an additional 991 shares during the last quarter. Magnolia Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $236,000. NewEdge Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 6.3% during the 2nd quarter. NewEdge Advisors LLC now owns 4,368 shares of the biopharmaceutical company’s stock worth $4,591,000 after acquiring an additional 260 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in Regeneron Pharmaceuticals by 16.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,821 shares of the biopharmaceutical company’s stock worth $4,016,000 after purchasing an additional 536 shares during the last quarter. Finally, Seaport Global Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 64.2% in the second quarter. Seaport Global Advisors LLC now owns 839 shares of the biopharmaceutical company’s stock valued at $882,000 after purchasing an additional 328 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.